Notification of Policy Revisions Effective September 1, 2021 (Posted July 1, 2021)
| Policy Name | Revision |
| Pulmonary Hypertension, Drug Management “Notification” | Requests for brand Remodulin require a trial and failure of generic treprostinil sodium. Policy notification given 7/1/2021 for effective date 9/1/2021. |
Blue Connect